BioStock: PHI tar in kapital för storsatsning på regenerativ medicin

April 8, 2022
Language flag

Phase Holographic Imaging har inlett en satsning på marknaden för regenerativ medicin, ett område man menar har potential att bota flera stora folksjukdomar. Med HoloMonitor utmanar bolaget dagens invasiva mikroskopbaserade tekniker. Bland kunderna återfinns flera kända namn som Bayer AG, amerikanska National Institutes of Health, Harvard och Stanford University samt Novo Nordisk. I syfte att finansiera satsningen, samt öka försäljningen ytterligare, genomför bolaget nu en företrädesemission. BioStock kontaktade CFO Patrik Eschricht för att få veta mer.

Läs hela intervjun med Patrik Eschricht på biostock.se.

Latest News

Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 2 December 2024

Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”) will hold an Extraordinary General Meeting on 2 December 2024 at 15.00 CET at the Company’s premises, Skiffervägen 48 in Lund.

PHI resolves on a fully secured rights issue of shares of approximately SEK 64.3 million

The Board of Directors of Phase Holographic Imaging PHI AB has today resolved on a rights issue of shares, with preferential rights for the Company’s existing shareholders, of approximately SEK 64.3 million before deduction of issue related costs, subject to approval by the extraordinary general meeting to be held on 2 December 2024. The purpose of the Rights Issue is to fund a strategic development plan and to strengthen the Company’s capital structure by repayment/off-setting of outstanding loans.

Adopting the final Annual Report

PHI intends to convene a general meeting to adopt the annual report for the fiscal year 2023/2024 and to amend resolutions regarding election of board members and the number of board members.
See All News